Audentes Therapeutics (BOLD) Tops Q4 EPS by 8c

Audentes Therapeutics (NASDAQ: BOLD) reported Q4 EPS of ($0.84), $0.08 better than the analyst estimate of ($0.92).

For earnings history and earnings-related data on Audentes Therapeutics (BOLD) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• The Buckle (BKE) Tops Q2 EPS by 7c, Beats on Revenue
• Is the global equity rally broadening? UBS weighs in